A proper GLP-1 evaluation should include: A complete medical history and review of current medications BMI and body composition assessment Blood work including metabolic panel, HbA1c, lipid panel, and thyroid function Cardiovascular risk assessment Discussion of realistic expectations, side effect management, and a plan for nutritional support Be cautious of any service that prescribes GLP-1 medications after a brief online questionnaire with no physician review
Mice that were treated with GLP-1MK-801 for 8 days displayed improved insulin sensitivity as assessed by an insulin tolerance test compared with mice that were treated with either monotherapy or vehicle (Fig
These findings matter for Lyme patients, since persistent inflammation and tissue damage are key drivers of symptoms
Though several molecules, such as mazdutide, a GLP/glucagon dual agonist, are being studied in various phases, the first agent targeting incretins other than just GLP-1 was approved in 2022 tirzepatide [41]
other weight loss medications is really a conversation about choice, safety, and long-term health
In clinical trials, GI side effects occur in roughly 4050% of patients on either medication, though they are typically mild to moderate and tend to improve over the first 812 weeks